UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549



FORM
10-Q



(Mark
One)



☒ QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934



For
the quarterly period ended September 30, 2020



☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934



For
the transition period from __________ to __________



Commission
File Number: 001-34861



INTELLIGENT
BUYING, INC.

(Exact
name of Registrant as specified in its charter)



|California                   |  | 20-0956471                              
|---------------------------- |  | ----------------------------------------
|(State
    of incorporation) |  | (I.R.S.
    Employer Identification No.)



340
Madison Avenue, 19th Floor

New
York, New York 10173

(Address
of principal executive offices) (zip code)



646-202-2897

(Registrant’s
telephone number, including area code)



Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐



Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files). Yes ☒    No ☐



Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



|Large
    accelerated filer | ☐ | Accelerated
    filer         | ☐
|--------------------------- | - | ----------------------------- | -
|Non-accelerated
    filer   | ☐ | Smaller
    reporting company | ☒
|                            |   | Emerging
    growth company   | ☐



If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
☐



Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐    No ☒



Securities
registered pursuant to Section 12(b) of the Act:



|Title
    of each class |  | Trading
    Symbol(s) |  | Name
    of each exchange on which registered
|----------------------- |  | --------------------- |  | ---------------------------------------------
|                        |  |                       |  |                                              
|                        |  |                       |  |                                              
|                        |  |                       |  |                                              



As
of November 23, 2020, 7,254,588 shares of common stock, par value $0.001 per share, were issued and outstanding.




















INTELLIGENT
BUYING, INC.



FORM
10-Q



September
30, 2020



TABLE
OF CONTENTS



|             |                                                                                                                                            | Page
    No.
|------------ | ------------------------------------------------------------------------------------------------------------------------------------------ | ------------
|             | PART
    I. - FINANCIAL INFORMATION                                                                                                        |             
|Item
    1.  | Financial
    Statements                                                                                                                   | 1           
|             | Consolidated
    Balance Sheets as of September 30, 2020 (Unaudited) and December 31, 2019                                                 | 1           
|             | Unaudited
    Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine months Ended September 30, 2020 and 2019 | 2           
|             | Unaudited
    Consolidated Statement of Changes in Stockholders’ Equity for the Nine months Ended September 30, 2020                       | 3           
|             | Unaudited
    Consolidated Statements of Cash Flows for the Nine months Ended September 30, 2020 and 2019                                  | 4           
|             | Notes
    to Unaudited Consolidated Financial Statements                                                                                   | 5           
|Item
    2.  | Management’s
    Discussion and Analysis of Financial Condition and Results of Operations                                                  | 12          
|Item
    3   | Quantitative
    and Qualitative Disclosures About Market Risk                                                                             | 16          
|Item
    4   | Controls
    and Procedures                                                                                                                | 16          
|             |                                                                                                                                            |             
|             | PART
    II - OTHER INFORMATION                                                                                                            |             
|             |                                                                                                                                            |             
|Item
    1.  | Legal
    Proceedings                                                                                                                      | 17          
|Item
    1A. | Risk
    Factors                                                                                                                           | 17          
|Item
    2.  | Unregistered
    Sales of Equity Securities and Use of Proceeds                                                                            | 17          
|Item
    3.  | Defaults
    upon Senior Securities                                                                                                        | 17          
|Item
    4.  | Mine
    Safety Disclosures                                                                                                                | 17          
|Item
    5.  | Other
    Information                                                                                                                      | 17          
|Item
    6.  | Exhibits                                                                                                                                   | 18          







i







FORWARD
LOOKING STATEMENTS



This
report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words
such as “expects,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking
statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this
report. Additionally, statements concerning future matters are forward-looking statements.



Although
forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based
on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties
and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking
statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those
specifically addressed under the headings “Risks Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in our annual report on Form 10-K, in “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and information contained in other reports
that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as
of the date of this report.



We
file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements,
and other information regarding issuers that file electronically with the SEC, including us. You can also read and copy any materials
we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional
information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330 .



We
undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that
may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various
disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks
and factors that may affect our business, financial condition, results of operations and prospects.



Unless
otherwise indicated, references in this report to “we,” “us” or the “Company” refer to Intelligent
Buying, Inc. and its subsidiaries.







ii







PART
1 - FINANCIAL INFORMATION



Item
1.  Financial Statements.



INTELLIGENT
BUYING, INC. AND SUBSIDIARIES

CONSOLIDATED
BALANCE SHEETS



(UNAUDITED)



|                                                                                                                                                                                  |  | September 30,
    2020 |            |   | December 31,
    2019 |  
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ---------------------- | ---------- | - | --------------------- | -
|ASSETS                                                                                                                                                                            |  |                        |            |   |                       |  
|CURRENT ASSETS                                                                                                                                                                    |  |                        |            |   |                       |  
|Cash                                                                                                                                                                              |  | $                      | 1,834      |   |                       | $
|Accounts Receivables                                                                                                                                                              |  |                        | 67,500     |   |                       |  
|Loan Receivable                                                                                                                                                                   |  |                        | -          |   |                       |  
|Investment                                                                                                                                                                        |  |                        | 10,000     |   |                       |  
|Advances to Supplier                                                                                                                                                              |  |                        | 134,874    |   |                       |  
|Inventory                                                                                                                                                                         |  |                        | 27,560     |   |                       |  
|TOTAL CURRENT
    ASSETS                                                                                                                                                          |  |                        | 241,768    |   |                       |  
|                                                                                                                                                                                  |  |                        |            |   |                       |  
|FIXED ASSETS (net of Depreciation)                                                                                                                                                |  |                        | 38,058     |   |                       |  
|OTHER ASSETS                                                                                                                                                                      |  |                        |            |   |                       |  
|Deposit                                                                                                                                                                           |  |                        | 12,043     |   |                       |  
|TOTAL
    ASSETS                                                                                                                                                                  |  | $                      | 291,869    |   |                       | $
|                                                                                                                                                                                  |  |                        |            |   |                       |  
|LIABILITIES AND STOCKHOLDERS’
    DEFICIENCY                                                                                                                                      |  |                        |            |   |                       |  
|CURRENT LIABILITIES                                                                                                                                                               |  |                        |            |   |                       |  
|Accounts payable and accrued expenses                                                                                                                                             |  | $                      | 119,892    |   |                       | $
|Loan payable – related party                                                                                                                                                      |  |                        | 220,805    |   |                       |  
|Loan Payable – other                                                                                                                                                              |  |                        | 256,500    |   |                       |  
|TOTAL CURRENT
    LIABILITIES                                                                                                                                                     |  |                        | 597,197    |   |                       |  
|STOCKHOLDERS’ DEFICIENCY                                                                                                                                                          |  |                        |            |   |                       |  
|Preferred Stock – Par Value of $0.001; 25,000,000 shares authorized;
    1,000.000 and 0 shares issued and outstanding as of September 30, 2020 and December 31, 2019             |  |                        | 1,000      |   |                       |  
|Common Stock - Par Value of $0.001; 50,000,000 shares authorized;
    7,254,588 and  7,975,003  shares issued and outstanding as of September 30, 2020  and December
    31, 2019 |  |                        | 7,254      |   |                       |  
|Additional paid-in capital                                                                                                                                                        |  |                        | 1,376,884  |   |                       |  
|Accumulated deficit                                                                                                                                                               |  |                        | (1,690,466 | ) |                       |  
|TOTAL STOCKHOLDERS’ DEFICIENCY                                                                                                                                                    |  |                        | (305,328   | ) |                       |  
|TOTAL
    LIABILITIES & STOCKHOLDERS’ DEFICIENCY                                                                                                                                  |  | $                      | 291,869    |   |                       | $



The
accompanying notes are an integral part of these unaudited consolidated financial statements.





1







INTELLIGENT
BUYING, INC. AND SUBSIDIARIES

UNAUDITED
STATEMENTS OF OPERATIONS



|                                                  |  | Three months ended
    September 30 |           |   | Nine months ended
    September 30 |  
|------------------------------------------------- |  | ----------------------------------- | --------- | - | ---------------------------------- | -
|                                                  |  | 2020                                |           |   | 2019                               |  
|                                                  |  |                                     |           |   |                                    |  
|REVENUES:                                         |  | $                                   | 166       |   |                                    | $
|TOTAL REVENUES                                    |  |                                     | -         |   |                                    |  
|                                                  |  |                                     |           |   |                                    |  
|Cost of sales                                     |  |                                     | -         |   |                                    |  
|                                                  |  |                                     |           |   |                                    |  
|Gross Profit                                      |  |                                     | 166       |   |                                    |  
|                                                  |  |                                     |           |   |                                    |  
|Operating Expenses                                |  |                                     |           |   |                                    |  
|Advertising and Marketing                         |  |                                     | -         |   |                                    |  
|Selling Expenses                                  |  |                                     | -         |   |                                    |  
|General and Administrative                        |  |                                     | 5,323     |   |                                    |  
|Legal and Professional                            |  |                                     | 11,400    |   |                                    |  
|Office rent                                       |  |                                     | -         |   |                                    |  
|Management Fees                                   |  |                                     | 5,692     |   |                                    |  
|Product development cost                          |  |                                     |           |   |                                    |  
|                                                  |  |                                     |           |   |                                    |  
|TOTAL OPERATING EXPENSES                          |  |                                     | 22,415    |   |                                    |  
|                                                  |  |                                     |           |   |                                    |  
|LOSS FROM
    OPERATIONS                          |  |                                     | (22,249   | ) |                                    |  
|                                                  |  |                                     |           |   |                                    |  
|INCOME TAX PROVISION                              |  |                                     |           |   |                                    |  
|Other Income (Expenses)                           |  |                                     |           |   |                                    |  
|NET LOSS                                          |  | $                                   | (22,249   | ) |                                    | $
|                                                  |  |                                     |           |   |                                    |  
|NET LOSS
    PER COMMON SHARE – BASIC AND DILUTED |  | $                                   | (0.003    | ) |                                    | $
|                                                  |  |                                     |           |   |                                    |  
|WEIGHTED AVERAGE NUMBER
    OF SHARES OUTSTANDING |  |                                     | 7,154,602 |   |                                    |  



The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.





2







INTELLIGENT
BUYING, INC. AND SUBSIDIARIES

UNAUDITED
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIENCY

For
the Nine Months Ended September 30, 2020



|                                                  |  | Common Stock |            |   | Preferred Stock |   |        | Additional Paid in |  |  | Accumulated |  |  |         |      
|------------------------------------------------- |  | ------------ | ---------- | - | --------------- | - | ------ | ------------------ |  |  | ----------- |  |  | ------- | -----
|                                                  |  | Shares       |            |   | Amount          |   |        | Shares             |  |  | Amount      |  |  | Capital |      
|Balance December 31, 2019                         |  |              | 7,975,003  |   |                 | $ | 7,975  |                    |  |  |             |  |  | $       |      
|Common stock issued                               |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Share exchange                                    |  |              | 702,111    |   |                 |   | 702    |                    |  |  | 1,000,000   |  |  |         | 1,000
|Issuance of common stock                          |  |              | 2,532,200  |   |                 |   | 2,532  |                    |  |  |             |  |  |         |      
|Common stock cancelled                            |  |              | (4,114,353 | ) |                 |   | (4,114 | )                  |  |  |             |  |  |         |      
|Net loss for three months period                  |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Balances March 31, 2020                           |  |              | 7,094,961  |   |                 |   | 7,095  |                    |  |  | 1,000,000   |  |  |         | 1,000
|                                                  |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Common stock issued                               |  |              | 159,627    |   |                 |   | 159    |                    |  |  |             |  |  |         |      
|Adjustment to paid in capital                     |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Net loss for three months period                  |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|                                                  |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Balances June 30, 2020                            |  |              | 7,254,588  |   |                 |   | 7,254  |                    |  |  | 1,000,000   |  |  |         | 1,000
|Net loss for the three months period              |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Balances September 30, 2020                       |  |              | 7,254,588  |   |                 |   | 7,254  |                    |  |  | 1,000,000   |  |  | $       | 1,000
|                                                  |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Balance - December 31, 2018                       |  |              | 7,256,600  |   |                 |   | 7,257  |                    |  |  |             |  |  |         | -    
|Common stock issued                               |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Net loss for three months ending March 31         |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Balances March 31, 2019                           |  |              | 7,256,600  |   |                 | $ | 7,257  |                    |  |  | -           |  |  |         | -    
|                                                  |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Common stock issued                               |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Net loss for three months  June 30,
    2019      |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|Balances June 30, 2019                            |  |              | 7,256,600  |   |                 | $ | 7,257  |                    |  |  | -           |  |  | $       | -    
|Net Loss for three months  September
    30, 2019 |  |              |            |   |                 |   |        |                    |  |  |             |  |  |         |      
|                                                  |  |              | 7,256,600  |   |                 | $ | 7,257  |                    |  |  | -           |  |  |         | -    



The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.





3









INTELLIGENT
BUYING, INC. AND SUBSIDIARIES

UNAUDITED
CONSOLIDATED STATEMENTS OF CASH FLOWS



|                                                                                |  | Nine Months ended |         
|------------------------------------------------------------------------------- |  | ----------------- | --------
|                                                                                |  | September 30,     |         
|                                                                                |  | 2020              |         
|OPERATING ACTIVITIES:                                                           |  |                   |         
|Net loss                                                                        |  | $                 | (552,840
|Adjustments to reconcile net loss to net cash used
    in operating activities: |  |                   |         
|Depreciation Expenses                                                           |  |                   | 3,765   
|Changes in operating assets and liabilities:                                    |  |                   |         
|Accounts Receivables                                                            |  |                   | (67,500 
|Inventory                                                                       |  |                   | (27,560 
|Loans receivables                                                               |  |                   | 7,611   
|Advances to supplier                                                            |  |                   | (11,874 
|Accounts payable and accrued
    expenses                                       |  |                   | (27,576 
|NET CASH
    USED IN OPERATING ACTIVITIES                                       |  |                   | (675,974
|INVESTMENT ACTIVITIES:                                                          |  |                   |         
|Purchase of office equipments                                                   |  |                   | (39,277 
|Deposit                                                                         |  |                   |         
|NET CASH
    USED IN INVESTMENT ACTIVITIES                                      |  |                   | (39,277 
|FINANCING ACTIVITIES:                                                           |  |                   |         
|Proceeds (Payment) of loan payable – other                                      |  |                   | (19,999 
|Proceeds from short term loan                                                   |  |                   | 256,500 
|Net proceeds from issuance
    of common stock                                  |  |                   | 471,560 
|NET CASH
    PROVIDED BY FINANCING ACTIVITIES                                   |  |                   | 708,061 
|INCREASE (DECREASE) IN CASH                                                     |  |                   | (7,190  
|                                                                                |  |                   |         
|CASH-BEGINNING OF PERIOD                                                        |  |                   | 9,024   
|CASH-END OF PERIOD                                                              |  | $                 | 1,834   
|Supplemental disclosures of
    cash flow information:                          |  |                   |         
|Cash paid during the year for:                                                  |  |                   |         
|Interest                                                                        |  | $                 |         
|Taxes                                                                           |  | $                 |         



The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.







4







INTELLIGENT
BUYING, INC. AND SUBSIDIARIES

NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER
30, 2020



NOTE
1 – ORGANIZATION AND NATURE OF OPERATIONS



On
February 14, 2020 (the “Closing Date”), we entered into and closed (the “Closing”) an Agreement and Plan
of Reorganization (the “Agreement”) with Cannavolve and each of the 37 shareholders of Cannavolve who executed a counterpart
signature to the Agreement (the “Cannavolve Shareholders”). Pursuant to the Agreement, the Company agreed to acquire
an aggregate of 33,674,262 shares of common stock of Cannavolve constituting 81.5% of the issued and outstanding shares of common
stock of Cannavolve from the Cannavolve Shareholders in exchange for 702,111 shares of common stock of the Company, constituting
9.6% of the issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”), of the
Company (the “Reorganization “). Pursuant to the Agreement, the Company agreed to file a Certificate of Determination
with the State of California, as soon as practicable after the Closing, to create a new class of preferred stock of the Company,
the Series B Preferred Stock (the “New Preferred”), and further agreed to issue, as a post-Closing covenant, 1,000,000
shares of the New Preferred to Principal Holdings, LLC (“Principal”), in consideration of Principal successfully negotiating
the Agreement and performing due-diligence in connection with the Agreement. Additionally, pursuant to the Agreement, the parties
agreed that the Company’s then principal shareholder, Bagel Hole Inc. (“Bagel Hole”), which is owned solely
by Philip Romanzi, the Company’s Chief Executive, Chief Financial Officer, Treasurer, Secretary and sole director, would
return to the Company for cancellation and retirement an aggregate of 4,114,352 shares of Common Stock owned by Bagel Hole. Additionally,
pursuant to the Agreement, the parties agreed that at Closing, (i) Mr. Romanzi would resign from all executive officer and director
positions with the Company, (ii) George Furlan would be appointed as the Company’s Interim Chief Executive Officer, Interim
Chief Financial Officer, Interim Treasurer, Interim Secretary and Chief Operating Officer, and (iii) Dante Jones would be appointed
as the Company’s sole director. Further, the parties agreed that two additional directors would be appointed to the Company’s
board of directors after Closing.



At
Closing pursuant to the Agreement: (i) we issued an aggregate of 702,111 shares of Common Stock to the Cannavolve Shareholders
in exchange for 33,674,262 shares of Cannavolve common stock, constituting 81.5% of the issued and outstanding shares of Cannavolve,
resulting in Cannavolve becoming our 81.5% owned subsidiary; (ii) Bagel Hole returned to INTB for cancellation and retirement
4,114,352 shares of Common Stock owned by Bagel Hole; (iii) Mr. Romanzi resigned from all officer and director positions with
the Company; (iv) George Furlan was appointed as the Company’s Interim Chief Executive Officer, Interim Chief Financial
Officer, Interim Treasurer, Interim Secretary and Chief Operating Officer; and (v) Dante Jones was appointed as the Company’s
sole director. We anticipate that, in the near future, the size of the Board will be increased to three directors.



In
addition, on May 28, 2020, the Company entered into and closed a Share Exchange Agreement (the “Share Exchange Agreement”)
with the remaining shareholders of Cannavolve (the “Remaining Cannavolve Shareholders”). Pursuant to the Share Exchange
Agreement, the Company acquired an aggregate of 7,656,441 shares of common stock of Cannavolve constituting 18.5% of the issued
and outstanding shares of common stock of Cannavolve from the Remaining Cannavolve Shareholders in exchange for 159,627 shares
of common stock of the Company, constituting 0.02% of the issued and outstanding shares of Common Stock of the Company and 1,000,000
shares of newly created Series B preferred stock (the “Share Exchange”). As a result of the Share Exchange, Cannavolve
is a wholly owned operating subsidiary of the Company. Additionally, on May 28, 2020, the Company’s Board of Directors (the
“Board) increased the size of the Board from one to two and George Furlan was appointed as a director to fill the vacancy.



The
offers, sales, and issuances of the securities described above were deemed to be exempt from registration under the Securities
Act in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and/or Rule 506 as promulgated under Regulation D
as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired
the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate
legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions
was an accredited or sophisticated person and had adequate access, through employment, business or other relationships, to information
about us.



On
July 14, 2020, shareholders holding a majority of the Company’s outstanding voting stock voted in favor of the following
corporate matters (the “Corporate Matters”) which relate to the approval to authorize (1) the amendment to the Company’s
Restated Articles of Incorporation to effect a forward stock split of all of the outstanding shares of common stock of the Company
at a ratio of seven for one (7:1) (the “Forward Split”), which such Forward Split will not impact the Company’s
authorized shares of Common Stock, (2) the amendment to the Company’s Restated Articles of Incorporation to increase in
the number of authorized shares of the Company’s Common Stock from 50,000,000 to 500,000,000 shares of common stock, (3)
the amendment to the Company’s Restated Articles of Incorporation to effect a change of the Company’s name from Intelligent
Buying, Inc. to Sentient Brands Holdings, Inc., and (4) changing the Company’s corporate domicile from California to Nevada.
The Corporate Matters are not yet effective.



Cannavolve



Cannavolve
was incorporated in the state of Washington on July 6, 2012. To date, Cannavolve’s operations have consisted primarily of
providing advisory and operational services to hemp and ancillary cannabis companies, serving as a business accelerator working
with startups and emerging brands nationwide. Headquartered in Seattle, Cannavolve has guided clients through every phase of the
startup process, including business planning and forecasting, funding and investment, human resources and legal operations and
manufacturing, and sales and marketing. Cannavolve’s go-to-market strategies and program implementation processes were designed
with one goal in mind: to drive innovation and position startups for sustainable momentum and growth.



Toward
the end of 2019, Cannavolve began to decrease its advisory and operational services to hemp and ancillary cannabis companies and
shifted its focus to product development, brand management and creating CBD lifestyle brands. Cannavolve’s mission is now
to launch and operate best-in-class brands in the Luxury, Premium and Mass Market space with an objective on innovation and product
uniqueness, derived from research insights, demographic data, customer interviews and omni-channel experiences.





5







We
value our Cannavolve customers’ personal well-being as much as we value the well-being of our planet. We believe in responsible
luxury that respects nature and humankind, a luxury that prepares for a better world for future generations. We believe that ethics
and moral values are becoming increasingly important for consumers in such a way that they are starting to strongly influence
their purchasing decisions. Environment, sustainability, cruelty-free production and labor practices are all elements now taken
into consideration when buying a product.



Our
full spectrum CBD used in our products is rich in Phytocannabinoids and is THC free. Our CBD is sustainably farmed and sourced.
We employ supercritical CO2 and alcohol extraction technologies without the use of any harsh chemicals. All of our CBD use in
our products is tested up to 20 times through cultivation, extraction and manufacturing process to final packaged product. Our
CBD is also vegan, gluten free, cruelty free and Non-GMO.



Each
of our portfolio brands is planned to have its own digital architecture which will allow us to closely monitor our sales channel
strategies and continually refine sales channels while exploring new ones which we believe represent the greatest potential. We
intend to build brand loyalty by endorsing consumer core values of authenticity and relatability and maintain a commitment to
following sustainable practices and rigorous product testing.



Principal
Products and Services



The
Company currently has one main product line and three in development. The Company’s current active product line is Revive
Now.



Revive
Now



Revive
Now a mass market, premium-quality, full spectrum, hemp-based CBD product brand. Revive Now offers quality
products at competitive market pricing, such as CBD-infused tinctures, softgels, creams, powders, gumdrops, and sprays. Products
currently sold under the Revive Now product line include:



| | ● | CBD-Infused
    Dried Fruits and Gummies
| | - | ----------------------------------------



| | ● | CBD
    Topicals
| | - | ----------------



| | ● | CBD
    Sprays
| | - | --------------



Revive
Now products are indented to provide a safe and effective way to consume hemp-based CBD.



Revive
NowTarget Market



Our
initial target demographic for the Revive Now brand is women over the age of 35. However, we intend to target
the mass market with this brand, selling to potential purchasers of any income and background. We believe anyone looking for support
for aches and pain, anxiety, inflammation, insomnia and depression are potential customers for the Revive Now brand.
We intend to target customers who are looking for CBD infused products at affordable price points.



Future
Product Lines



The
Company has three product lines planned for introduction.



| | ● | Ouevre -
    a next generation CBD luxury skin care line and lifestyle brand.
| | - | -----------------------------------------------------------------------------



| | ● | F.A.M.E. -
    a millennial, premium priced dual-gender lifestyle brand
| | - | -----------------------------------------------------------------------



| | ● | LevelLab –a
    premium priced millennial fitness/wellness/performance product line
| | - | -----------------------------------------------------------------------------------



Ouevre



Oeuvre- ”A
Body of Art” – with a planned launch in Fall 2020, is intended to be a next generation CBD luxury skin care
line and lifestyle brand. Planned product offerings under this line include



| | ● | Purifying
    Exfoliator
| | - | ------------------------



| | ● | Replenishing
    Oil
| | - | --------------------



| | ● | Ultra-Nourishing
    Face Cream
| | - | -------------------------------



| | ● | Revitalizing
    Eye Cream
| | - | --------------------------



| | ● | High
    Potency Tincture
| | - | -------------------------



| | ● | CBD
    infused and scented candles
| | - | -----------------------------------



| | ● | CBD
    infused women’s fragrance
| | - | ---------------------------------



Drawing
inspiration from petals, leaves, roots, minerals and gemstones, Ouevre celebrates the artistry of well-being
and beauty, inside and out. Ouevre products are non-toxic, ungendered products made with zero GMO, retinyl palmitate,
petroleum, mineral oil, parabens, sulfates, and synthetic colors.





6







OuevreTarget
Market



Ouevre is
planned to be our luxury segment product line. With Ouevre, we are targeting a large and influential consumer class
of the of individuals that are “HENRYs” – High-Earners-Not-Rich-Yet. They have discretionary income and are
highly likely to be wealthy in the future. HENRYs earn between $100,000 and $250,000 annually. They are digitally fluent, love
online shopping online, and are big discretionary spenders. Therefore, ouvreskincare.com offers inclusive, aspirationally affordable
luxury products positioned for them.



We
believe the benefit of onboarding this demographic to Ouevre are twofold: securing valuable present customers
and building relationships and business with those most likely to be amongst the most affluent consumers in the future. By the
year 2025, Millennials and Generation Z will represent more than 40% of the overall luxury goods market, according to a 2019 report
published by Boston Consulting Group. We seek to target such group for the sale of our Ouevre products.

On
social media, we will target the following audiences for the Ouevre brand



| | ● | Women
    aged 30+
| | - | ------------------



| | ● | Luxury
    Skincare Enthusiasts
| | - | -------------------------------



| | ● | CBD
    Enthusiasts
| | - | -------------------



| | ● | Crystal
    Lovers
| | - | ------------------



| | ● | Wellness
    Audience
| | - | ---------------------



| | ● | Makeup
    Artists
| | - | ------------------



| | ● | Art
| | - | ---



| | ● | Beauty
| | - | ------



| | ● | Influencers
| | - | -----------



| | ● | Bloggers
| | - | --------



| | ● | Stores
| | - | ------



LevelLab



We
intend LevelLab to be a premium priced millennial fitness, wellness, and performance product line, with a planned
launch of 2021. Intended products include:



| | ● | Therapeutic
    recovery cream that provides heating and cooling effects to sooth pain, containing isolate hemp CBD, 100% THC free.
| | - | -----------------------------------------------------------------------------------------------------------------------------------



| | ● | LevelLab
    Bundle including daily facial cleanser, hyaluronic and vitamin C moisturizer, and retinol night cream.
| | - | -------------------------------------------------------------------------------------------------------------------



| | ● | LevelLab
    Active Hydration – supplement for mineral replenishment and optimal hydration for before, during, and after
    workout.
| | - | -------------------------------------------------------------------------------------------------------------------------------------



| | ● | LevelLab
    Fuel – a recovery drink containing a unique combination of CBD and amino acids.
| | - | --------------------------------------------------------------------------------------------



LevelLabTarget
Market



We
plan to target Millennials (generally ages 23 – 38 as of 2019) for our LevelLab product line. These consumers,
who came of age in a hyper-connected, digital world, have unique shopping preferences, spend their time in different mediums,
and respond to a different style of messaging than generations past. This evolution in consumer behavior accompanies a significant
transition of purchasing power to the Millennial generation. According to the 2015 U.S. Census Bureau, Millennials accounted for
more than 25% of the U.S. population, exceeding the number of baby boomers and making it the largest percentage of the workforce
in the United States. Further, according to the U.S. Bureau of Labor Statistics, people born after 1981, including Millennials
and Generation Z, accounted for approximately $1.7 trillion or 22% of the nation’s total consumer expenditure in 2017. We
expect this number to significantly increase as Millennials enter their peak earning years and an increasing percentage of Generation
Z joins the workforce.



F.A.M.E



F.A.M.E. will
merge health and wellness with art and entertainment to curate unique and impactful products, content, and activities for a global
community, with a planned launch of 2021. As stated in a 2017 article on the Wellness industry published by Forbes, 72% of millennials
would rather spend money on experiences than on material goods. With F.A.M.E., we intend to give them both. Products
and offerings under the F.A.M.E. brand name are currently under development.



F.A.M.ETarget
Market



The
target market for F.A.M.E.is also Millennials. We intend to market F.A.M.E.to premium consumers
– both male and female – in the Millennial market.







7







NOTE
2 – BASIS OF PRESENTATION AND GOING CONCERN



Basis
of presentation



These
interim consolidated financial statements of the Company and its subsidiaries are unaudited. In the opinion of management, all
adjustments (consisting of normal recurring accruals) and disclosures necessary for a fair presentation of these interim condensed
consolidated financial statements have been included. The results reported in the unaudited condensed consolidated financial statements
for any interim periods are not necessarily indicative of the results that may be reported for the entire year. The accompanying
unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities
and Exchange Commission and do not include all information and footnotes necessary for a complete presentation of financial statements
in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). The Company’s
unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant
intercompany accounts and transactions have been eliminated in consolidation.



Certain
information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance
with U.S. GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction
with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on May 29, 2020.



Going
concern



The
Company currently has limited operations. These unaudited consolidated financial statements have been prepared assuming that the
Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction
of liabilities in the normal course of business.



On
April 18, 2020, the Company, through its subsidiary Jaguaring Company, entered into Paycheck Protection Program Promissory Note
and Agreement with KeyBank National Association, pursuant to which the Company received loan proceeds of $231,500 (the “PPP
Loan”). The PPP Loan was made under, and is subject to the terms and conditions of, the PPP which was established under
the CARES Act and is administered by the U.S. Small Business Administration. The term of the PPP Loan is two years with a maturity
date of April 18, 2022 and contains a favorable fixed annual interest rate of 1.00%. Payments of principal and interest on the
PPP Loan will be deferred for the first six months of the term of the PPP Loan until November 18, 2020. Principal and interest
are payable monthly and may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Under the terms
of the CARES Act, recipients can apply for and receive forgiveness for all or a portion of loans granted under the PPP. Such forgiveness
will be determined, subject to limitations, based on the use of loan proceeds for certain permissible purposes as set forth in
the PPP, including, but not limited to, payroll costs (as defined under the PPP) and mortgage interest, rent or utility costs
(collectively, “Qualifying Expenses”), and on the maintenance of employee and compensation levels during the eight-week
period following the funding of the PPP Loan. The Company has been using the proceeds of the PPP Loan, for Qualifying Expenses.
However, no assurance is provided that the Company will be able to obtain forgiveness of the PPP Loan in whole or in part.



There
is no assurance that the Company will ever be profitable or be able to secure funding or generate sufficient revenues to sustain
operations. As such, there is substantial doubt about the Company’s ability to continue as a going concern. These unaudited
condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to
continue as a going concern.



Covid-19



A
novel strain of coronavirus (“Covid-19”) emerged globally in December 2019 and has been declared a pandemic. The extent
to which Covid-19 will impact our customers, business, results and financial condition will depend on current and future developments,
which are highly uncertain and cannot be predicted at this time. While the Company’s day-to-day operations beginning March
2020 have been impacted, we have suffered less immediate impact as most staff can work remotely and can continue to develop our
product offerings.



That
said, we have seen our business opportunities develop more slowly as business partners and potential customers are dealing with
Covid-19 issues, working remotely and these issues are causing delays in decision making and finalization of negotiations and
agreements.







8







As
reflected in the accompanying unaudited consolidated financial statements, the Company had an accumulated deficit of $1,690,466
at September 30, 2020 and had a net loss and net cash flow used in operating activities of $552,840 and $675,974 for the nine months
ended September 30, 2020, respectively. The Company has a limited operating history and its continued growth is dependent upon
the continuation of selling its products; hence generating revenues and obtaining additional financing to fund future obligations
and pay liabilities arising from normal business operations. In addition, the current cash balance cannot be projected to cover
the operating expenses for the next twelve months from the release date of this report.  These matters raise substantial
doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern
is dependent on the Company’s ability to raise additional capital, implement its business plan, and generate significant
revenues. There are no assurances that the Company will be successful in its efforts to generate significant revenues, maintain
sufficient cash balance or report profitable operations or to continue as a going concern. The Company plans on raising capital
through the sale of equity or debt instruments to implement its business plan. However, there is no assurance these plans will
be realized and that any additional financings will be available to the Company on satisfactory terms and conditions, if any.



The
accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability
or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company
be unable to continue as a going concern.



NOTE
3 - SIGNIFICANT ACCOUNTING POLICIES



Uses
of estimates in the preparation of financial statements



The
preparation of financial statements in conformity with generally accepted accounting principles accepted in the United States
of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of net revenue and expenses during each reporting period. Actual results could differ from those estimates.



Cash



The
Company considers all short-term highly liquid investments with an original maturity date of purchase of six months or less to
be cash equivalents.



Revenue
Recognition



During
the nine months ended September 30, 2020 our revenue recognition policy was in accordance with ASC 605, “Revenue Recognition”,
which requires the recognition of sales when there is evidence of a sales agreement, the delivery of goods has occurred, the sales
price is fixed or determined and the collectability of revenue is reasonably assured.



On
January 1, 2019, the Company adopted ASU 2014-09, “Revenue from Contracts with Customers” and all the related amendments,
which are also codified into ASC 606. The adoption of this guidance did not have a material effect on the Company’s financial
position, results of operations or cash flows.



Net
loss per common share – basic and diluted



Authoritative
guidance on Earnings per Sharerequires dual presentation of basic and diluted earnings or loss per share (“EPS”)
for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS
computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution; diluted EPS reflects
the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.



Basic
loss per share is computed by dividing net loss applicable to common shareholders by the weighted average number of common shares
outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if dilutive securities
and other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common
stock that then shared in the earnings of the Company, unless the effect is to reduce a loss or increase earnings per share.



Stock-based
compensation



In
accordance with ASC No. 718, Compensation – Stock Compensation (“ASC 718”), the Company measures
the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in
the financial statements over the period during which employees are required to provide services.



During
the nine months ended September 30, 2020 and the year ended December 31, 2019, there were no stock based awards issued or outstanding.







9







Fair
value of financial instruments



We
value our financial assets and liabilities on a recurring basis using the fair value hierarchy established in Accounting Standards
Codification (“ASC”) 820, Fair Value Measurements and Disclosures.



ASC
820 describes three levels of inputs that may be used to measure fair value, as follows:



Level 1
input, which include quoted prices in active markets for identical assets or liabilities;



Level 2
inputs, which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities;
quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
or can be corroborated by observable market data for substantially the full term of the asset or liability; and



Level 3
inputs, which include unobservable inputs that are supported by little or no market activity and that are significant to the fair
value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are
determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management
judgment or estimation.



Income
Taxes



Deferred
taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating
loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences
are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced
by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred
tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates
on the date of enactment. The U.S. federal income tax rate is 21%.



The
provision for Federal income tax consists of the following September 30, 2020 and 2019:



|Federal income tax attributable to:  |  | September 30,
    2020 |          |   | September 30,
    2019 |  
|------------------------------------ |  | ---------------------- | -------- | - | ---------------------- | -
|Current operations                   |  | $                      | 115,832  |   |                        | $
|Less: Valuation allowance            |  |                        | (115,832 | ) |                        |  
|Net provision for Federal income tax |  |                        | -        |   |                        |  



The
cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows:



|Deferred tax assets attributable to: |  | September 30,
    2020 |          |   | December 31,
    2019 |  
|------------------------------------ |  | ---------------------- | -------- | - | --------------------- | -
|Net operating loss carry over        |  | $                      | 354,730  |   |                       | $
|Less: Valuation allowance            |  |                        | (354,730 | ) |                       |  
|Net deferred tax assets              |  |                        | -        |   |                       |  



NOTE
4 - ADVANCES TO SUPPLIER



Advances
to supplier consist of single vendor where the company have placed an order of branded CBD products worth $308,030 on the November
11, 2019. As of September 30, 2020 the balance represents 60% of the total value of the order committed.



NOTE
5 - LOAN PAYABLE- OTHER



Since
the change of control of the Company in May 2018, we have received advances from Pure Energy 714 LLC, an unaffiliated entity,
with an outstanding balance of $220,804 as of December 31, 2018, at which time there was no formal arrangement between the Company
and Pure Energy 714 LLC regarding the terms for repayment of these advances. Following further advances aggregating $84,128 during
the year ended December 31, 2019, an amount of $240,803 was outstanding as of December 31, 2019. On March 15, 2019, specific terms
were reached on $70,757 of such advances pursuant to an unsecured convertible promissory note entered into between the Company
and Pure Energy 714 LLC, the terms call for repayment of the advances including interest on any unconverted principal amount at
a rate of 4% per annum and a repayment date on or before August 15, 2022. Additional terms include a voluntary conversion option,
pursuant to which Pure Energy 714 LLC may convert any outstanding balance at $0.05 per share into shares of common stock.  On
January 3, 2020, specific terms were reached on the remaining $150,046 of such advances pursuant to an unsecured demand note entered
into between the Company and Pure Energy 714 LLC, the terms call for repayment of the advances including interest on any unconverted
principal amount at a rate of 12% per annum and a repayment date on or before June 3, 2021 at the rate of 12% per annum. If the
demand note is unpaid by June 3, 2021, default interest of 3% monthly will apply.



The
Company has accrued interest of $23,236 on these notes.





10







NOTE
6 - COMMITMENTS AND CONTINGENCIES



COVID-19



On
March 11, 2020, the World Health Organization announced that infections of the novel Coronavirus (COVID-19) had become pandemic,
and on March 13, the U.S. President announced a National Emergency relating to the disease. There is a possibility of continued
widespread infection in the United States and abroad, with the potential for catastrophic impact. National, state and local authorities
have required or recommended social distancing and imposed or are considering quarantine and isolation measures on large portions
of the population, including mandatory business closures. These measures, while intended to protect human life, are expected to
have serious adverse impacts on domestic and foreign economies of uncertain severity and duration. Some economists are predicting
the United States will soon enter a recession. The sweeping nature of the coronavirus pandemic makes it extremely difficult to
predict how the Company’s business and operations will be affected in the longer run, but we expect that it may materially
affect our business, financial condition and results of operations. The extent to which the coronavirus impacts our results will
depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge
concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. Moreover,
the coronavirus outbreak has begun to have indeterminable adverse effects on general commercial activity and the world economy,
and our business and results of operations could be adversely affected to the extent that this coronavirus or any other epidemic
harms the global economy generally and/or the markets in which we operate specifically. Any of the foregoing factors, or other
cascading effects of the coronavirus pandemic that are not currently foreseeable, could materially increase our costs, negatively
impact our revenues and damage the Company’s results of operations and its liquidity position, possibly to a significant
degree. The duration of any such impacts cannot be predicted.



The
Company previously entered into an employment agreement with an employee effective as of February 28, 2019 (the “Employment
Agreement”) pursuant to which the employee was to assist in advancing the Company’s business plan in consideration
of a base salary of $10,000 per month (the “Base Salary”). On March 24, 2020, the employee provided the Company with
written notice that, effective as of April 1, 2020, the employee voluntarily agreed to suspend the Base Salary indefinitely. On
August 12, 2020, the employee tendered his written resignation to the Company terminating his employment with the Company and
the Employment Agreement effective as of August 12, 2020. Accordingly, the Company accrued an expense of $10,000 per month until
April 1, 2020 in connection with the Employment Agreement.



NOTE
7 - PREFERRED STOCK



The
Company is authorized to issue 25,000,000 shares of Preferred Stock, par value $.001 per share. As of September 30, 2020, 1,000,000
shares of Series B Preferred Stock were issued and outstanding.



For
five years from the date of issuance, the Series B Preferred Stock shall have the number of votes equal to fifty-one
percent (51%) of the cumulative total vote of all classes of stock of the Corporation, common or preferred, whether such other
class of stock is voting as a single class or the other classes of stock are voting together as a single group, and with respect
to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common
Stock, or any other class of preferred stock, and shall be entitled to notice of any stockholders’ meeting  in accordance
with the bylaws of the Corporation, and shall be entitled to vote, together with holders of Common Stock and any class of preferred
stock entitled to vote, with respect to any question upon which holders of Common Stock or any class of preferred stock have the
right to vote. After five years, the Series B Preferred Stock shall automatically, and without further action by the Corporation,
be cancelled and void, and may not be reissued.



NOTE
8 - SUBSEQUENT EVENTS



The
Company evaluates events and transactions occurring subsequent to the date of the condensed consolidated financial statements
for matters requiring recognition or disclosure in the condensed consolidated financial statements. The accompanying condensed
consolidated financial statements consider events through the date on which the condensed consolidated financial statements were
available to be issued.



Impact
of COVID-19 Pandemic



In
December 2019, a novel coronavirus disease (“COVID-19”) was reported and in January 2020, the World Health Organization
(“WHO”) declared it a Public Health Emergency of International Concern. On February 28, 2020, the WHO raised its assessment
of the COVID-19 threat from high to very high at a global level due to the continued increase in the number of cases and affected
countries, and on March 11, 2020, the WHO characterized COVID-19 as a pandemic.



As
of the date of this filing, our primary suppliers continue to be operating. However, the broader implications of COVID-19 on our
results of operations and overall financial performance remain uncertain. We may experience constrained supply or other business
disruptions that could materially impact our business, results of operations and overall financial performance in future periods.
See Risk Factors for further discussion of the possible impact of the COVID-19 pandemic on our business.





11







ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS



The
following discussion and analysis of the results of operations and financial condition of Intelligent Buying, Inc. for the nine
months ended September 30, 2020 and 2019 should be read in conjunction with the Intelligent Buying, Inc. unaudited condensed consolidated
financial statements and the notes thereto contained elsewhere in this report. Our discussion includes forward-looking statements
based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions.
Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as
a result of a number of factors, including those set forth under the Risk Factors, Special Note Regarding Forward-Looking Statements
and Business sections in our Form 10-K as filed with the Securities and Exchange Commission on May 29, 2020. We use words such
as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,”
“expect,” “believe,” “intend,” “may,” “will,” “should,”
“could,” and similar expressions to identify forward-looking statements  .



Unless
otherwise indicated, references to the “Company,” “us” or “we” refer to Intelligent Buying,
Inc. and its subsidiaries.



Overview



On
February 14, 2020 (the “Closing Date”), we entered into and closed (the “Closing”) an Agreement and Plan
of Reorganization (the “Agreement”) with Cannavolve and each of the 37 shareholders of Cannavolve who executed a counterpart
signature to the Agreement (the “Cannavolve Shareholders”). Pursuant to the Agreement, the Company agreed to acquire
an aggregate of 33,674,262 shares of common stock of Cannavolve constituting 81.5% of the issued and outstanding shares of common
stock of Cannavolve from the Cannavolve Shareholders in exchange for 702,111 shares of common stock of the Company, constituting
9.6% of the issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”), of the
Company (the “Reorganization “). Pursuant to the Agreement, the Company agreed to file a Certificate of Determination
with the State of California, as soon as practicable after the Closing, to create a new class of preferred stock of the Company,
the Series B Preferred Stock (the “New Preferred”), and further agreed to issue, as a post-Closing covenant, 1,000,000
shares of the New Preferred to Principal Holdings, LLC (“Principal”), in consideration of Principal successfully negotiating
the Agreement and performing due-diligence in connection with the Agreement. Additionally, pursuant to the Agreement, the parties
agreed that the Company’s then principal shareholder, Bagel Hole Inc. (“Bagel Hole”), which is owned solely
by Philip Romanzi, the Company’s Chief Executive, Chief Financial Officer, Treasurer, Secretary and sole director, would
return to the Company for cancellation and retirement an aggregate of 4,114,352 shares of Common Stock owned by Bagel Hole. Additionally,
pursuant to the Agreement, the parties agreed that at Closing, (i) Mr. Romanzi would resign from all executive officer and director
positions with the Company, (ii) George Furlan would be appointed as the Company’s Interim Chief Executive Officer, Interim
Chief Financial Officer, Interim Treasurer, Interim Secretary and Chief Operating Officer, and (iii) Dante Jones would be appointed
as the Company’s sole director. Further, the parties agreed that two additional directors would be appointed to the Company’s
board of directors after Closing.



At
Closing pursuant to the Agreement: (i) we issued an aggregate of 702,111 shares of Common Stock to the Cannavolve Shareholders
in exchange for 33,674,262 shares of Cannavolve common stock, constituting 81.5% of the issued and outstanding shares of Cannavolve,
resulting in Cannavolve becoming our 81.5% owned subsidiary; (ii) Bagel Hole returned to INTB for cancellation and retirement
4,114,352 shares of Common Stock owned by Bagel Hole; (iii) Mr. Romanzi resigned from all officer and director positions with
the Company; (iv) George Furlan was appointed as the Company’s Interim Chief Executive Officer, Interim Chief Financial
Officer, Interim Treasurer, Interim Secretary and Chief Operating Officer; and (v) Dante Jones was appointed as the Company’s
sole director. We anticipate that, in the near future, the size of the Board will be increased to three directors.



In
addition, on May 28, 2020, the Company entered into and closed a Share Exchange Agreement (the “Share Exchange Agreement”)
with the remaining shareholders of Cannavolve (the “Remaining Cannavolve Shareholders”). Pursuant to the Share Exchange
Agreement, the Company acquired an aggregate of 7,656,441 shares of common stock of Cannavolve constituting 18.5% of the issued
and outstanding shares of common stock of Cannavolve from the Remaining Cannavolve Shareholders in exchange for 159,627 shares
of common stock of the Company, constituting 0.02% of the issued and outstanding shares of Common Stock of the Company (the “Share
Exchange”). As a result of the Share Exchange, Cannavolve is a wholly owned operating subsidiary of the Company. Additionally,
on May 28, 2020, the Company’s Board of Directors (the “Board) increased the size of the Board from one to two and
George Furlan was appointed as a director to fill the vacancy.



The
offers, sales, and issuances of the securities described above were deemed to be exempt from registration under the Securities
Act in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and/or Rule 506 as promulgated under Regulation D
as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired
the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate
legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions
was an accredited or sophisticated person and had adequate access, through employment, business or other relationships, to information
about us.



Cannavolve



Cannavolve
was incorporated in the state of Washington on July 6, 2012. To date, Cannavolve’s operations have consisted primarily of
providing advisory and operational services to hemp and ancillary cannabis companies, serving as a business accelerator working
with startups and emerging brands nationwide. Headquartered in Seattle, Cannavolve has guided clients through every phase of the
startup process, including business planning and forecasting, funding and investment, human resources and legal operations and
manufacturing, and sales and marketing. Cannavolve’s go-to-market strategies and program implementation processes were designed
with one goal in mind: to drive innovation and position startups for sustainable momentum and growth.





12









Toward
the end of 2019, Cannavolve began to decrease its advisory and operational services to hemp and ancillary cannabis companies and
shifted its focus to product development, brand management and creating CBD lifestyle brands. Cannavolve’s mission is now
to launch and operate best-in-class brands in the Luxury, Premium and Mass Market space with an objective on innovation and product
uniqueness, derived from research insights, demographic data, customer interviews and omni-channel experiences.



We
value our Cannavolve customers’ personal well-being as much as we value the well-being of our planet. We believe in responsible
luxury that respects nature and humankind, a luxury that prepares for a better world for future generations. We believe that ethics
and moral values are becoming increasingly important for consumers in such a way that they are starting to strongly influence
their purchasing decisions. Environment, sustainability, cruelty-free production and labor practices are all elements now taken
into consideration when buying a product.



Our
full spectrum CBD used in our products is rich in Phytocannabinoids and is THC free. Our CBD is sustainably farmed and sourced.
We employ supercritical CO2 and alcohol extraction technologies without the use of any harsh chemicals. All of our CBD use in
our products is tested up to 20 times through cultivation, extraction and manufacturing process to final packaged product. Our
CBD is also vegan, gluten free, cruelty free and Non-GMO.



Each
of our portfolio brands is planned to have its own digital architecture which will allow us to closely monitor our sales channel
strategies and continually refine sales channels while exploring new ones which we believe represent the greatest potential. We
intend to build brand loyalty by endorsing consumer core values of authenticity and relatability and maintain a commitment to
following sustainable practices and rigorous product testing.



Principal
Products and Services



The
Company currently has one main product line and three in development. The Company’s current active product line is Revive
Now.



Revive
Now



Revive
Now a mass market, premium-quality, full spectrum, hemp-based CBD product brand. Revive Now offers quality
products at competitive market pricing, such as CBD-infused tinctures, softgels, creams, powders, gumdrops, and sprays. Products
currently sold under the Revive Now product line include:



| | ● | CBD-Infused
    Dried Fruits and Gummies
| | - | ----------------------------------------



| | ● | CBD
    Topicals
| | - | ----------------



| | ● | CBD
    Sprays
| | - | --------------



Revive
Now products are indented to provide a safe and effective way to consume hemp-based CBD.



Revive
NowTarget Market



Our
initial target demographic for the Revive Now brand is women over the age of 35. However, we intend to target
the mass market with this brand, selling to potential purchasers of any income and background. We believe anyone looking for support
for aches and pain, anxiety, inflammation, insomnia and depression are potential customers for the Revive Now brand.
We intend to target customers who are looking for CBD infused products at affordable price points.



Future
Product Lines



The
Company has three product lines planned for introduction.



| | ● | Ouevre -
    a next generation CBD luxury skin care line and lifestyle brand.
| | - | -----------------------------------------------------------------------------



| | ● | F.A.M.E. -
    a millennial, premium priced dual-gender lifestyle brand
| | - | -----------------------------------------------------------------------



| | ● | LevelLab –a
    premium priced millennial fitness/wellness/performance product line
| | - | -----------------------------------------------------------------------------------



Ouevre



Oeuvre- ”A
Body of Art” – with a planned launch in Fall 2020, is intended to be a next generation CBD luxury skin care
line and lifestyle brand. Planned product offerings under this line include



| | ● | Purifying
    Exfoliator
| | - | ------------------------



| | ● | Replenishing
    Oil
| | - | --------------------





| | ● | Ultra-Nourishing
    Face Cream
| | - | -------------------------------



| | ● | Revitalizing
    Eye Cream
| | - | --------------------------





13









| | ● | High
    Potency Tincture
| | - | -------------------------



| | ● | CBD
    infused and scented candles
| | - | -----------------------------------



| | ● | CBD
    infused women’s fragrance
| | - | ---------------------------------



Drawing
inspiration from petals, leaves, roots, minerals and gemstones, Ouevre celebrates the artistry of well-being
and beauty, inside and out. Ouevre products are non-toxic, ungendered products made with zero GMO, retinyl palmitate,
petroleum, mineral oil, parabens, sulfates, and synthetic colors.



OuevreTarget
Market



Ouevre is
planned to be our luxury segment product line. With Ouevre, we are targeting a large and influential consumer class
of the of individuals that are “HENRYs” – High-Earners-Not-Rich-Yet. They have discretionary income and are
highly likely to be wealthy in the future. HENRYs earn between $100,000 and $250,000 annually. They are digitally fluent, love
online shopping online, and are big discretionary spenders. Therefore, ouvreskincare.com offers inclusive, aspirationally affordable
luxury products positioned for them.



We
believe the benefit of onboarding this demographic to Ouevre are twofold: securing valuable present customers
and building relationships and business with those most likely to be amongst the most affluent consumers in the future. By the
year 2025, Millennials and Generation Z will represent more than 40% of the overall luxury goods market, according to a 2019 report
published by Boston Consulting Group. We seek to target such group for the sale of our Ouevre products.

On
social media, we will target the following audiences for the Ouevre brand



| | ● | Women
    aged 30+
| | - | ------------------



| | ● | Luxury
    Skincare Enthusiasts
| | - | -------------------------------



| | ● | CBD
    Enthusiasts
| | - | -------------------



| | ● | Crystal
    Lovers
| | - | ------------------



| | ● | Wellness
    Audience
| | - | ---------------------



| | ● | Makeup
    Artists
| | - | ------------------



| | ● | Art
| | - | ---



| | ● | Beauty
| | - | ------



| | ● | Influencers
| | - | -----------



| | ● | Bloggers
| | - | --------



| | ● | Stores
| | - | ------



LevelLab



We
intend LevelLab to be a premium priced millennial fitness, wellness, and performance product line, with a planned
launch of 2021. Intended products include:



| | ● | Therapeutic
    recovery cream that provides heating and cooling effects to sooth pain, containing isolate hemp CBD, 100% THC free.
| | - | -----------------------------------------------------------------------------------------------------------------------------------



| | ● | LevelLab
    Bundle including daily facial cleanser, hyaluronic and vitamin C moisturizer, and retinol night cream.
| | - | -------------------------------------------------------------------------------------------------------------------



| | ● | LevelLab
    Active Hydration – supplement for mineral replenishment and optimal hydration for before, during, and after
    workout.
| | - | -------------------------------------------------------------------------------------------------------------------------------------



| | ● | LevelLab
    Fuel – a recovery drink containing a unique combination of CBD and amino acids.
| | - | --------------------------------------------------------------------------------------------



LevelLabTarget
Market



We
plan to target Millennials (generally ages 23 – 38 as of 2019) for our LevelLab product line. These consumers,
who came of age in a hyper-connected, digital world, have unique shopping preferences, spend their time in different mediums,
and respond to a different style of messaging than generations past. This evolution in consumer behavior accompanies a significant
transition of purchasing power to the Millennial generation. According to the 2015 U.S. Census Bureau, Millennials accounted for
more than 25% of the U.S. population, exceeding the number of baby boomers and making it the largest percentage of the workforce
in the United States. Further, according to the U.S. Bureau of Labor Statistics, people born after 1981, including Millennials
and Generation Z, accounted for approximately $1.7 trillion or 22% of the nation’s total consumer expenditure in 2017. We
expect this number to significantly increase as Millennials enter their peak earning years and an increasing percentage of Generation
Z joins the workforce.







14











F.A.M.E



F.A.M.E. will
merge health and wellness with art and entertainment to curate unique and impactful products, content, and activities for a global
community, with a planned launch of 2021. As stated in a 2017 article on the Wellness industry published by Forbes,, 72% of millennials
would rather spend money on experiences than on material goods. With F.A.M.E., we intend to give them both. Products
and offerings under the F.A.M.E. brand name are currently under development.



F.A.M.ETarget
Market



The
target market for F.A.M.E.is also Millennials. We intend to market F.A.M.E.to premium consumers
– both male and female – in the Millennial market.



RESULTS
OF OPERATIONS



Comparison
of Results of Operations for the Nine months Ended September 30, 2020 and 2019



Revenue



We
acquired Cannavolve on February 14, 2020 where we consolidated our financial statements since then. The Company provides advisory
and operational services to hemp and ancillary cannabis companies, serving as a full-service business accelerator working with
startups and emerging brands nationwide. The Company accelerates customer’s businesses through a proven model of funding;
operations; product launches; and ongoing sales, marketing, and expansion into new markets. Each customer arrangement is unique
and revenue is recognized, both over time and at a point in time, depending upon the performance obligations stated in the contract.
During the nine months ending September 30, 2020 total revenues reported was $19,219, have no revenues for the nine months period
ending September 30, 2019.



Cost
of Revenue



Cost of
revenue includes the cost of internal labor and related benefits, travel expenses related to consulting services, subcontractor
costs, other related consulting costs, and other overhead costs. During the nine months ending September 30, 2020 the cost of
revenue was $9,509.



Gross
Margin



Gross
Profit for the nine months ending September 30, 2020 is $9,710 or 51% of total revenues. We expect to keep our gross profit at
about 40% in the next quarter.



Operating
Expenses



For
the nine months ended September 30, 2020 and 2019, operating expenses consisted of the following:



|                           |  | Nine months ended
    September 30, |        
|-------------------------- |  | ----------------------------------- | -------
|                           |  | 2020                                |        
|Advertising and Marketing  |  | $                                   | 32,162 
|Selling Expenses           |  |                                     | 22,020 
|General and Administrative |  |                                     | 134,544
|Legal and Professional     |  |                                     | 231,133
|Office rent                |  |                                     | 16,351 
|Management Fees            |  |                                     | 158,718
|Product development cost   |  |                                     | 26,200 
|TOTAL OPERATING EXPENSES   |  | $                                   | 621,128



| | ● | Our
    advertising and marketing mainly include consulting fees for branding, social media and creation of marketing materials for
    our brand.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | ● | Selling
    expense mainly includes our marketing and sales staff’s salaries and related benefits, and travel and entertainment
    costs incurred by our sales department.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
| | ● | Legal
    and professional fees primarily consisted of accounting fees, legal service fees, consulting fees, investor relations service
    charges and other fees incurred for service related to becoming and being a public company. For nine months ended September
    30, 2020, professional fees increase over the same period in 2019 as mainly attributable to an increase in fees of approximately
    $70,000 incurred for services performed by our marketing consultant, and an increase in legal services fees of approximately
    $36,000. We expect professional fees to increase as we incur significant costs associated with our public company reporting
    requirements, and costs associated with newly applicable corporate governance requirements, including requirements under the
    Sarbanes-Oxley Act of 2002 and other rules implemented by the Securities and Exchange Commission.
| | ● | Office
    rent are monthly lease payments for our principal executive offices in New York.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
| | ● | Our
    management fees comprise mainly of salaries paid our management staff. The nine months period ending September 30, 2020 the
    increase in management fee mainly attributable to the salaries of our Chief Financial Officer and directors approximately
    $60,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
| | ● | Product
    development cost includes packaging supplies and materials, design and marketing consultants approximately $26,200 for the
    nine months period ending September 30, 2020, there were no product development cost incurred for the nine months period ending  September
    30, 2019.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 







15







Loss
from Operations



The
Company’s net loss for the nine-month period ended September 30, 2020 and 2019 was $552,840 and $130,288, respectively.



Income
Taxes



We
did not have any income taxes expense for the nine months ended September 30, 2020 and 2019 since we incurred losses in the periods.



Liquidity
and Capital Resources



Covid
19



A
novel strain of coronavirus (“Covid-19”) emerged globally in December 2019 and has been declared a pandemic. The extent
to which Covid-19 will impact our customers, business, results and financial condition will depend on current and future developments,
which are highly uncertain and cannot be predicted at this time. While the Company’s day-to-day operations beginning March
2020 have been impacted, we have suffered less immediate impact as most staff can work remotely and can continue to develop our
product offerings.



That
said we have seen our business opportunities develop more slowly as business partners and potential customers are dealing with
Covid-19 issues, working remotely and these issues are causing delays in decision making and finalization of negotiations and
agreements.



Contractual
Obligations and Off-Balance Sheet Arrangements



Contractual
Obligations



We
presently do not have any contractual obligations.



Off-balance
Sheet Arrangements



We
presently do not have off-balance sheet arrangements.



Inflation



The
effect of inflation on our revenue and operating results was not significant.



ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.



As
a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required
by this Item.



ITEM
4. CONTROLS AND PROCEDURES



Evaluation
of Disclosure Controls and Procedures



Changes
in Internal Controls over Financial Reporting



There
were no changes (including corrective actions with regard to material weakness) in our internal controls over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect,
our internal control over financial reporting.





16









PART
II - OTHER INFORMATION



ITEM
1. LEGAL PROCEEDINGS



From
time to time, we are subject to ordinary routine litigation incidental to our normal business operations. We are not currently
a party to any litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably
expected to have a material adverse effect on our business, operating results, cash flows or financial condition.



ITEM
1A. RISK FACTORS



Risk
factors describing the major risks to our business can be found under Item 1A, “Risk Factors”, in our Annual Report
on Form 10-K for the year ended December 31, 2019. There has been no material change in our risk factors from those previously
discussed in the Annual Report on Form 10-K.



ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS



On
May 28, 2020, the Company entered into and closed a Share Exchange Agreement (the “Share Exchange Agreement”) with
the remaining shareholders of Cannavolve (the “Cannavolve Shareholders”). Pursuant to the Share Exchange Agreement,
the Company acquired an aggregate of 7,656,441 shares of common stock of Cannavolve constituting the remaining 18.5% of the issued
and outstanding shares of common stock of Cannavolve from the Cannavolve Shareholders in exchange for 159,627 shares of common
stock of the Company, constituting 0.02% of the issued and outstanding shares of Common Stock of the Company (the “Share
Exchange”). As a result of the Share Exchange, Cannavolve is a wholly owned operating subsidiary of the Company.



The
offers, sales, and issuances of the securities described above were deemed to be exempt from registration under the Securities
Act in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and/or Rule 506 as promulgated under Regulation D
as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired
the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate
legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions
was an accredited or sophisticated person and had adequate access, through employment, business or other relationships, to information
about us.



ITEM
3. DEFAULTS UPON SENIOR SECURITIES



None.



ITEM
4. MINE SAFETY DISCLOSURES



None.



ITEM
5. OTHER INFORMATION



None.





17









ITEM
6. EXHIBITS



The
following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.





|Exhibit
    No. |  | Exhibit
    Description                                                                                                                                                                                                                                                                                                                                                  
|--------------- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|2.1             |  | Reorganization
    Agreement between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve, and the Cannavolve shareholders listed in
    the agreement, dated March 13, 2019 (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form
    8-K filed with the SEC on March 19, 2019).                                                 
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|2.2             |  | Amended
    Reorganization Agreement between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve and the Cannavolve shareholders
    listed in the agreement, dated April 27, 2019 (incorporated by reference to Exhibit 99.2 to the Company’s Current Report
    on Form 8-K filed with the SEC on May 6, 2019).                                             
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|2.3             |  | Amendment
    No. 1 to Reorganization Agreement between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve, and the Cannavolve
    shareholders listed in the agreement, dated April 27, 2019 (incorporated by reference to Exhibit 99.3 to the Company’s
    Current Report on Form 8-K filed with the SEC on May, 6 2019).                                 
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|2.4             |  | Second
    Amended Agreement and Plan of Reorganization between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve Holdings,
    the Cannavolve Shareholders listed in the agreement dated January 2, 2020 (incorporated by reference to Exhibit 99.1 to the
    Company’s Current Report on Form 8-K filed with the SEC on January 8, 2020).                
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|2.5             |  | Termination
    Agreement of the Reorganization between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve Holdings, the Cannavolve
    Shareholders listed in the agreement dated February 12, 2020. (Incorporated by reference to the Form 8-K Current Report filed
    with the Securities and Exchange Commission on February 14, 2020).                 
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|2.6             |  | Agreement
    and Plan of Reorganization by and among Intelligent Buying Inc., Jaguaring Company d/b/a Cannavolve Holdings and the Cannavolve
    Shareholders listed in the agreement dated February 14, 2020. (Incorporated by reference to the Form 8-K Current Report filed
    with the Securities and Exchange Commission on February 14, 2020).                   
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|3.1             |  | Articles
    of Incorporation of Intelligent Buying Inc. and Certificate of Amendment of Articles of Incorporation of Intelligent Buying,
    Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form SB-2 filed with the SEC
    on April 17, 2006).                                                                             
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|3.2             |  | Bylaws
    of Intelligent Buying, Inc. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange
    Commission on February 14, 2020).                                                                                                                                                                                            
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|3.3             |  | Certificate
    of Determination for Series A Convertible Preferred Stock of Intelligent Buying, Inc. (incorporated by reference to Exhibit
    4.2 to the Company’s Registration Statement on Form SB-2 filed with the SEC on April 17, 2006).                                                                                                                          
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|3.4             |  | Certificate
    of Determination for Series B Preferred Stock of Intelligent Buying, Inc. (Incorporated by reference to the Form 8-K Current
    Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                         
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|10.1            |  | Convertible
    Promissory Note of Intelligent Buying Inc. issued to PureEnergy714 LLC2019 (incorporated by reference to Exhibit 99.2 to the
    Company’s Current Report on Form 8-K filed with the SEC on March 19, 2019).                                                                                                                                             
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|10.2            |  | Convertible
    Promissory Note issued by Jaguaring, Inc. d/b/a Cannavolve (incorporated by reference to Exhibit 99.3 to the Company’s
    Current Report on Form 8-K filed with the SEC on March 19, 2019).                                                                                                                                                             
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|10.3            |  | Form
    of Subscription Agreement for Rule 506 Offering. (Incorporated by reference to the Form 8-K Current Report filed with the
    Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                         
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|10.4            |  | Executive
    Consulting Agreement between Intelligent Buying, Inc. and James Mansour dated January 8, 2020. (Incorporated by reference
    to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                      
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|10.5            |  | Employment
    Agreement between Intelligent Buying, Inc. and George V. Furlan dated December 2019. (Incorporated by reference to the Form
    8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                               
|                |  |                                                                                                                                                                                                                                                                                                                                                                          
|10.6            |  | Independent
                                         Contractor Agreement between Jaguaring Inc. d/b/a Cannavolve and Dante Jones dated May
                                         1, 2019. (Incorporated by reference to the Form 8-K Current Report filed with the Securities
                                         and Exchange Commission on February 14, 2020).







18









|10.7    |  | Addendum
    to Independent Contractor Agreement between Jaguaring Inc. d/b/a Cannavolve and Dante Jones dated September 20, 2019. (Incorporated
    by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                     
|------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.8    |  | Independent
    Contractor Agreement between Jaguaring Inc. d/b/a Cannavolve and Eric Swaney dated May 1, 2019. (Incorporated by reference
    to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                                        
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.9    |  | Addendum
    to Independent Contractor Agreement between Jaguaring Inc. d/b/a Cannavolve and Eric Swaney dated May 1, 2019. (Incorporated
    by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                            
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.10   |  | Office
    Agreement for Jaguaring Inc. d/b/a Cannavolve dated May 23, 2018. (Incorporated by reference to the Form 8-K Current Report
    filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                                                                           
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.11   |  | Promissory
    Note issued by Jaguaring Inc. d/b/a Cannavolve dated June 11, 2019. (Incorporated by reference to the Form 8-K Current Report
    filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                                                                     
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.12   |  | Promissory
    Note issued by Jaguaring Inc. d/b/a Cannavolve dated June 6, 2019. (Incorporated by reference to the Form 8-K Current Report
    filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                                                                      
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.13   |  | Employment
    Agreement between Intelligent Buying, Inc. and Gregg Templeton dated February 28, 2019. (Incorporated by reference to the
    Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                                                 
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.14*+ |  | Restricted
    Stock Purchase Agreement between Intelligent Buying, Inc. and James Mansour.                                                                                                                                                                                                                                                                                                                                                                   
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.15*+ |  | Restricted
    Stock Purchase Agreement between Intelligent Buying, Inc. and George Furlan. (Incorporated by reference to the Form 8-K Current
    Report filed with the Securities and Exchange Commission on February 14, 2020).                                                                                                                                                                                                                            
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|10.16   |  | Share
                                         Exchange Agreement dated as of May 28, 2020 by and among Intelligent Buying Inc., and
                                         the shareholders of Jaguaring Company d/b/a Cannavolve Holdings. (Incorporated by reference
                                         to the Form 10-K Annual Report filed with the Securities and Exchange Commission on May
                                         29, 2020).
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|14.1    |  | Code
    of Ethics of Intelligent Buying, Inc. (incorporated by reference to Exhibit 14.1 to the Company’s Registration Statement
    on Form SB-2 filed with the SEC on April 17, 2006).                                                                                                                                                                                                                                                                     
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|31.1*   |  | Certification
    of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.                                                                                                                                                                                                                                                                                           
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|31.2*   |  | Certification
    of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.                                                                                                                                                                                                                                                                                           
|        |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|32.1*   |  | Certification
    of Chief Executive Officer & Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
    906 of the Sarbanes-Oxley Act of 2002                                                                                                                                                                                                                                                                           



**
XBRL to be filed by amendment.





19







SIGNATURES



Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.



|                            | INTELLIGENT
    BUYING, INC.
|--------------------------- | ----------------------------
|                            | (Registrant)                
|                            |                             
|Date:
    November 23, 2020 | By:                         
|                            |                             
|                            |                             
|                            |                             
|Date:
    November 23, 2020 | By:                         
|                            |                             
|                            |                             







20